Andrew Gendron


Andrew Gendron is a partner in the Baltimore office of Lewis Brisbois and a member of the National Trial Practice and Complex Business & Commercial Litigation Practice. He has tried nearly 100 cases to verdict, practiced throughout the United States, and is skilled in handling mass and class actions and multidistrict litigation in product liability, toxic tort, environmental, and stockholder/corporate-governance matters, as well as actions concerning fiduciary duties and professional liability. Mr. Gendron frequently works with transactional attorneys to provide deal-related risk management advice. His clients have included pharmaceutical companies, petroleum refiners, chemical manufacturers, real estate investment trusts (REITs), banks, law firms, and high-net-worth individuals.

Mr. Gendron’s trial experience includes the following representative matters:

  • Won a defense verdict in wrongful-death action alleging that occupational exposure to benzene caused decedent’s acute myelogenous leukemia 
  • Won a defense verdict for manufacturer of woodworking equipment against claim that a design defect had caused permanent disabling injury to a medical doctor’s dominant hand
  • Won a defense verdict in multiparty death and personal-injury case arising from a vehicular accident where a tractor-trailer entered an active highway work site
  • Won a defense verdict for a community association sued by an invitee who became quadriplegic as a result of diving accident
  • Won a defense verdict for a go-kart manufacturer sued by parents of a nine-year-old who sustained internal injuries in a crash at an amusement park
  • Won a defense verdict for an automobile manufacturer and dealer accused of fraud for allegedly selling a repaired vehicle as new
  • Obtained dismissal of securities fraud claims against an early-stage biotechnology company, and then settled remaining, potentially crippling claims on terms that allowed the client to recapitalize
  • Obtained dismissal of a multi-million-dollar legal malpractice complaint on forum non convenient grounds, then filed offensive action for outstanding receivables in a more convenient forum, won dismissal of all counterclaims with prejudice, and obtained a favorable settlement for the client
  • Defended a petroleum refiner against groundwater contamination suits filed by more than 1,100 plaintiffs alleging property damage and personal injury, which ended as a victory for the client after trial, appeal, and settlements
  • Served on the national counsel teams for manufacturers of prescription pharmaceuticals, including as head of expert development team
  • Served as trial and liaison counsel in Maryland tobacco litigation, which included a defense verdict in one death case and dismissal of all tobacco/asbestos synergy cases filed in Baltimore City
  • Represented a wholesale food distributor and its parent in litigation involving breach-of-contract and wrongful-termination claims by distributor’s former CEO, and clients’ counterclaims for the CEO’s wrongful conduct, resulting in confidential resolution
  • Defended pigment and paint manufacturers before the trial and appellate courts of Maryland, with defense judgment upheld on appeal
  • Won a seven-year battle over alleged housing discrimination in a case of first impression, with an appellate mandate ordering dismissal of the charges at the administrative level
Andrew Gendron
Rated by Super Lawyers

loading ...

Primary Area(s) of Practice

  • Class Action & Mass Tort
  • Complex Business & Commercial Litigation
  • Directors & Officers Litigation
  • Products Liability
  • Professional Liability
  • Toxic Tort & Environmental Litigation
  • National Trial Practice
  • COVID-19: Commercial & Contractual Litigation Disputes
  • Asbestos Litigation




US District Courts

US Courts of Appeals


  • Member, American Bar Association
  • Life Fellow, American Bar Foundation
  • Member, International Association of Defense Counsel
  • Member, Maryland State Bar Association
  • Member, Bar Association of Baltimore City
  • Member, Baltimore County Bar Association
  • Member, District of Columbia Bar Association
  • Member, Defense Research Institute
  • Member, Maryland Defense Counsel
  • Past faculty member, Maryland Institute for Continuing Professional Education of Lawyers
  • Past faculty member, Maryland Institute for Trial Advocacy

Awards & Honors

  • Best Lawyers in America® - 'Best Lawyers' Commercial Litigation (2024)
  • Recognized in Maryland Super Lawyers, 2012 - 2022
  • Recognized in Super Lawyers Business Edition, Business Litigation, Baltimore, 2012 - 2019
  • Exceptional Service Award, United States District Court for the District of Maryland, 2015
  • Maryland State Bar Association People's Pro Bono Award, 1992
  • AV® Peer-Review-Rated (5.0/5.0) by Martindale-Hubbell
Andrew Gendron
Rated by Super Lawyers

loading ...

Professional Presentations

Co-Presenter, Genomic Analysis in Tort Cases: “Use of Genomics in Medical Cases (Birth Defects, Malpractice, Drugs),” Perrin Conferences, May 26, 2021


University of Maryland

Juris Doctor, 1986

Georgetown University

Bachelor of Arts, 1982

Pro Bono & Philanthropy

  • Represents minors and their families in special immigrant juvenile status (SIJS) proceedings through his work with Esperanza Center
  • Former chair, mission & planning and executive committees; former finance committee member, Catholic Community of Saint Francis Xavier (CCSFX)
  • Lay children’s and youth minister, lector, CCSFX
  • Co-chair, 19th and 20th Lawyers' Campaigns for CollegeBound Foundation
  • Former trustee (finance, education, and formation committees), Saint Mary’s Seminary & University
  • Former board member, Homeless Persons Representation Project
  • Former volunteer, Our Daily Bread
  • Former volunteer, Christopher Place


  • Andrew Gendron and Thomas M. Morgan, MD, "Incomplete Penetrance: Whole-Exome Sequencing and Federal Courts," For The Defense (Jan. 2019).
  • Andrew Gendron and Emily Kelley, “Getting the ‘Drift’: Maryland Adopts Daubert Standard,” IADC Business Litigation Committee Newsletter (Sep. 2020).